Middle East & Africa Biosimilars Market Size & Outlook

Name: Middle East & Africa Biosimilars Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The biosimilars market in Middle East & Africa is expected to reach a projected revenue of US$ 2,762.5 thousand by 2033. A compound annual growth rate of 18.5% is expected of Middle East & Africa biosimilars market from 2026 to 2033.

Middle East & Africa biosimilars drug class outlook (Revenue, USD thousand, 2021-2033)
- Monoclonal Antibodies (mAbs)
- Growth Factors & Hematopoietic Agents
- Insulin & Analogues
- Osteoporosis / Bone Metabolism Agents
- Others
Middle East & Africa biosimilars indication outlook (Revenue, USD thousand, 2021-2033)
- Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
- Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
- Diabetes Mellitus (Type 1 & Type 2)
- Ophthalmic Disorders (Wet AMD, DME, RVO)
- Hematologic / Rare Blood Disorders
- Others
Middle East & Africa biosimilars end use outlook (Revenue, USD thousand, 2021-2033)
- Hospitals
- Specialty Pharmacies
- Online & Retail Channels

Middle East & Africa Biosimilars Market Size & Outlook

Sign up - it's easy, and free!